Fosun Kairos | 复星凯瑞
Biotechnology Research • 
Kunshan, Jiangsu, China • 51-100 Employees
Company overview
| Headquarters | No.777 Shengrong Road, 3F, Office Building, Shanghai, Shanghai 201210, CN |
| Phone number | +862152212192 |
| Website | |
| NAICS | 541714 |
| Keywords | Immunotherapy, Cell Therapy, Car-T |
| Founded | 2017 |
| Employees | 51-100 |
| Socials |
Key Contacts at Fosun Kairos | 复星凯瑞
Monica Li
Director Of Corporate Communication And Public Relations
Robin Shang
Associate Director Of Strategic Platform
Li Shu
Associate Hr Director
Xingrong Chen
Chief Executive Officer, Fosunkite Biotechnology
Tracy Chen
Talent Acquisition Director
Hebby He
Associate Director Of Manufacturing And Technology Science
Annie Li
Associate Director, Communications & Public Relations
Xiaojiao Zhao
Medical Science Director-Cell And Gene Therapy
Hoho Song
The Associate Director, Medical Science Liaison
Jialiang Geng
Marketing Head-Senior Director
Fosun Kairos | 复星凯瑞 Email Formats
Fosun Kairos | 复星凯瑞 uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@fosunkairos.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@fosunkairos.com | 100% |
About Fosun Kairos | 复星凯瑞
Being founded in 2017 and a division of Fosun Pharma, Shanghai Fosun Kairos Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise. Fosun Kairos, since its establishment, has committed to the R&D, industrialization and commercialization of cell therapies against tumors, with the mission of "Cure the Incurable, Enlighten the Life" and its vision to be a most valuable leading one in the field of cell and gene therapy. Fosun Kairos has introduced Yescarta®, a CAR-T therapy for treating relapsed or refractory non-Hodgkin lymphoma, from U.S. Kite Pharma and localized its production in China. In June 2021, Fosun Kairos received approval to launch China's first CAR-T therapy, YIKAIDA (Axicabtagene Ciloleucel Injection, a local version of Yescarta®). In June 2023, YIKAIDA was approved for another indication, i.e., the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. The launch of YIKAIDA marked the inaugural year of CAR-T therapy in China and continues to drive high-quality progress in lymphoma treatment. Fosun Kairos has established a cell-therapy R&D center and a technology platform covering over 2000 square meters in Zhangjiang, Shanghai. Assembling a team of skilled scientists with high academic qualification from both domestic and abroad, the Company is dedicated to the early-stage research and development as well as evidence-based clinical projects of CAR-T, through technology license-in, independent innovation and cooperative development, aiming to build a sustainable innovation pipeline in cell therapy. Looking forward, Fosun Kairos will function as the core platform for Fosun Pharma's cell therapy technologies, concentrating on tumor immunotherapy with a goal to reach the global market. It aims to become a worldwide leader in cell therapy, offering more hope for cures to patients globally.
Fosun Kairos | 复星凯瑞 revenue & valuation
| Annual revenue | $10,000,000 |
| Revenue per employee | $132,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $32,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Fosun Kairos | 复星凯瑞 has 12 employees across 6 departments.
Departments
Number of employees
Funding Data
Fosun Kairos | 复星凯瑞 has never raised funding before.
Canada
Spain
United States
Belgium
Frequently asked questions
4.8
40,000 users
